Srinivas Akkaraju, M.D., Ph.D., has served as a one of our directors since July 2019. Dr. Akkaraju is a Founder and Managing General Partner at Samsara BioCapital. Previously, from April 2013 to February 2016, he served as a General Partner of Sofinnova Ventures. From January 2009 until April 2013, he served as Managing Director of New Leaf Venture Partners. Previously, he served as a Managing Director at Panorama Capital, LLC, a private equity firm. Prior to co-founding Panorama Capital, he was with J.P. Morgan Partners, which he joined in 2001 and of which he became a Partner in 2005. From October 1998 to April 2001, he was in Business and Corporate Development at Genentech, Inc. (now a wholly owned member of The Roche Group), a biotechnology company, most recently as Senior Manager.
Prior to joining Genentech, Dr. Akkaraju was a graduate student at Stanford University, where he received his M.D. and a Ph.D. in Immunology. He received his undergraduate degrees in Biochemistry and Computer Science from Rice University. Dr. Akkaraju also serves as a director of Seattle Genetics, Intercept Pharmaceuticals, Syros Pharmaceuticals, and Aravive. Previously, Dr. Akkaraju served as a director on the boards of Barrier Therapeutics, Eyetech Pharmaceuticals, ZS Pharma, Synageva Biopharma Corp., aTyr Pharma, and Amarin Corporation plc.
What is Srinivas Akkaraju's net worth?
The estimated net worth of Srinivas Akkaraju is at least $72.15 million as of December 21st, 2023. Dr. Akkaraju owns 1,786,427 shares of Chinook Therapeutics stock worth more than $72,153,787 as of April 23rd. This net worth evaluation does not reflect any other assets that Dr. Akkaraju may own. Learn More about Srinivas Akkaraju's net worth.
How do I contact Srinivas Akkaraju?
Has Srinivas Akkaraju been buying or selling shares of Chinook Therapeutics?
Srinivas Akkaraju has not been actively trading shares of Chinook Therapeutics during the past quarter. Most recently, on Monday, November 15th, Srinivas Akkaraju bought 1,215,000 shares of Chinook Therapeutics stock. The stock was acquired at an average cost of $14.00 per share, with a total value of $17,010,000.00. Learn More on Srinivas Akkaraju's trading history.
Who are Chinook Therapeutics' active insiders?
Are insiders buying or selling shares of Chinook Therapeutics?
In the last twelve months, insiders at the sold shares 3 times. They sold a total of 26,123 shares worth more than $586,102.54. The most recent insider tranaction occured on August, 1st when insider Andrew James King sold 1,168 shares worth more than $45,587.04. Insiders at Chinook Therapeutics own 16.8% of the company.
Learn More about insider trades at Chinook Therapeutics. Information on this page was last updated on 8/1/2023.
